NTRK2 FUSIONS

1 - 81 . (canceled)

82 . A compound capable of specifically inhibiting a TRIM24:NTRK2, AFAP1:NTRK2, or PAN3:NTRK2 fusion, wherein the fusion results in aberrant activity or expression of NTRK2, or overexpression NTRK2, and wherein the compound is an antibody that specifically binds to a TRIM24:NTRK2, AFAP1:NTRK2, or PAN3:NTRK2 fusion protein or an RNA inhibitor that hybridizes under stringent conditions to a TRIM24:NTRK2, AFAP1:NTRK2, or PAN3:NTRK2 gene fusion.

83 . The compound of claim 82 , wherein

(a) the antibody specifically binds to:

(i) a fragment of SEQ ID NO:3 comprising at least amino acids 665-674 of SEQ ID NO:3;

(ii) a fragment of SEQ ID NO:4 comprising at least amino acids 665-674 of SEQ ID NO:4;

(iii) a fragment of SEQ ID NO:6 comprising at least amino acids 544-553 of SEQ ID NO:6; or

(iv) a fragment of SEQ ID NO:8 comprising at least amino acids 138-147 of SEQ ID NO:8; and

(b) the RNA inhibitor hybridizes under stringent conditions to:

(i) a fragment of SEQ ID NO:1 comprising at least nucleotides 2010-2019 of SEQ ID NO:1;

(ii) a fragment of SEQ ID NO:2 comprising at least nucleotides 2000-2009 of SEQ ID NO:2;

(iii) a fragment of SEQ ID NO:5 comprising at least nucleotides 1641-1650 of SEQ ID NO:5; or

(iv) a fragment of SEQ ID NO:7 comprising at least nucleotides 426-435 of SEQ ID NO:7.

84 . A method for detecting the presence of an NTRK2 fusion selected from an AFAP1:NTRK2 gene fusion, a PAN3:NTRK2 gene fusion, a TRIM24:NTRK2 protein fusion, an AFAP1:NTRK2 protein fusion, and a PAN3:NTRK2 protein fusion in a patient, said method comprising:

a) contacting a biological sample from the patient with a reagent that specifically binds to the fusion junction of the NTRK2 fusion, and detecting binding between the NTRK2 fusion and the reagent; or

b) amplifying or sequencing a portion of a nucleic acid from the patient, and detecting the presence of a nucleotide sequence comprising at least the fusion junction of the NTRK2 fusion.

85 . The method of claim 84 , wherein the NTRK2 fusion to be detected is an NTRK2 gene fusion that comprises SEQ ID NO:5 or 7, or a portion of SEQ ID NO:5 or 7, wherein the portion encodes a polypeptide having NTRK2 kinase activity and comprises the fusion junction.

86 . The method of claim 85 , wherein the reagent is an oligonucleotide that hybridizes to the fusion junction of the NTRK2 gene fusion under stringent conditions.

87 . The method of claim 86 , wherein the oligonucleotide hybridizes under stringent conditions to

(a) a fragment of SEQ ID NO:5 comprising at least nucleotides 1641-1650 of SEQ ID NO:5; or

(b) a fragment of SEQ ID NO:7 comprising at least nucleotides 426-435 of SEQ ID NO:7.

88 . The method of claim 84 , wherein the NTRK2 fusion to be detected is an NTRK2 fusion protein that comprises SEQ ID NO:3, 4, 6, or 8, or a portion of SEQ ID NO:3, 4, 6, or 8, wherein the portion has NTRK2 kinase activity and comprises the fusion junction.

89 . The method of claim 88 , wherein the reagent is an antibody that specifically binds to the NTRK2 fusion protein, but does not specifically bind to wild-type NTRK2 or wild-type TRIM24, AFAP1, or PAN3.

90 . The method of claim 89 , wherein the antibody specifically binds to

(a) a fragment of SEQ ID NO:3 comprising at least amino acids 665-674 of SEQ ID NO:3;

(b) a fragment of SEQ ID NO:4 comprising at least amino acids 665-674 of SEQ ID NO:4;

(c) a fragment of SEQ ID NO:6 comprising at least amino acids 544-553 of SEQ ID NO:6; or

(d) a fragment of SEQ ID NO:8 comprising at least amino acids 138-147 of SEQ ID NO:8.

91 . The method of claim 84 , further comprising administering to the patient a therapeutically effective amount of an NTRK2 inhibitor or an NTRK2 fusion inhibitor.

92 . The method of claim 84 , wherein the patient is suffering from or susceptible to a cancer.

93 . The method of claim 92 , wherein the cancer is lung adenocarcinoma, low grade glioma, squamous cell carcinoma, or head and neck squamous cell carcinoma